Intent Required To Show Suppression And Inequitable Conduct
Client Alert | 1 min read | 07.19.06
In Flex-Rest, LLC v. Steelcase, Inc . (No. 05-1354, -1367; July 13, 2006), a Federal Circuit panel affirms a jury verdict of invalidity of one Flex-Rest patent and a grant of summary judgment that Steelcase did not infringe another Flex-Rest patent, both patents relating to computer keyboard positioning systems. It also affirms the district court's denial of Steelcase's motion for a determination of inequitable conduct in procuring the patent found to be invalid.
In the district court, Flex-Rest argued that Steelcase's KBS device did not qualify as prior art because it had suppressed or concealed the invention of that device. Steelcase's patent application was filed about six and one-half months after its reduction to practice, and Steelcase unveiled its KBS device at a trade show at about the same time. This time period between reduction to practice and filing was not considered to be an unreasonable delay, and Flex-Rest was deemed to have failed to provide any evidence of an intent to withhold the KBS device from the public. Thus, insufficient evidence is present to support a jury instruction regarding an inference of suppression or concealment.
With regard to inequitable conduct, the panel considers a letter and photographs from a competitor that were received by Flex-Rest's patent counsel. The letter containing the photographs was dated May 14, 1996, and the photographs, which were undated, were identified in the letter as showing equipment embodied in “the Seiler patent.” Flex-Rest's patent counsel did not consider the photographs to be credible evidence of prior art. Moreover, he considered the photographs to be cumulative of a patent disclosed to the PTO and thus did not disclose them as well. In light of this evidence, the district court is found not to have abused its discretion in finding that Flex-Rest's patent counsel lacked intent to mislead the PTO.
Insights
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.
Client Alert | 6 min read | 06.26.26
Client Alert | 4 min read | 06.25.26
Twin Executive Orders Seek to Spur Quantum Leap in Technology and Cybersecurity
Client Alert | 7 min read | 06.24.26
